Patents Assigned to BRICKELL BIOTECH, INC.
-
Publication number: 20220298108Abstract: A cocrystal containing the 1?R-diastereomer and the 1?S-diastereomer of sofpironium bromide at a ratio of 1:3 (Form CO), a crystal mixture (for example, Form B) containing Form CO and a crystalline form of the 1?R-diastereomer (Form MN), and a method for preparing sofpironium bromide, which is suitable for manufacture of the crystal mixture are provided. Form CO and a crystalline form of sofpironium bromide containing Form CO (for example, Form B) have superior stability without hygroscopic property, and accordingly they can be preferably used as a raw material of medicaments.Type: ApplicationFiled: May 22, 2020Publication date: September 22, 2022Applicants: Kaken Pharmaceutical Co., Ltd., Brickell Biotech, Inc.Inventors: Kazuyoshi MARUBAYASHI, Masahito WATANABE, Herbert R. BRINKMAN
-
Publication number: 20210395197Abstract: A cocrystal containing the 1?R-diastereomer and the 1?S-diastereomer of sofpironium bromide at a ratio of 1:3 (Form CO), a crystal mixture (for example, Form B) containing Form CO and a crystalline form of the 1?R-diastereomer (Form MN), and a method for preparing sofpironium bromide, which is suitable for manufacture of the crystal mixture are provided. Form CO and a crystalline form of sofpironium bromide containing Form CO (for example, Form B) have superior stability without hygroscopic property, and accordingly they can be preferably used as a raw material of medicaments.Type: ApplicationFiled: June 30, 2021Publication date: December 23, 2021Applicants: Kaken Pharmaceutical Co., Ltd., Brickell Biotech, Inc.Inventors: Kazuyoshi MARUBAYASHI, Masahito WATANABE, Herbert R. BRINKMAN
-
Publication number: 20210178135Abstract: An applicator and applicator system are provided for a topically or transdermally applying a pharmaceutical preparation or formulation. The applicator and applicator system can reduce drip during use, provide efficient transfer of a dose of the pharmaceutical preparation or formulation from the applicator to the skin of a patient, and can be used hands-free, which can reduce, prevent or eliminate cross-contamination to other areas, including undesired application to other parts of the skin or to other individuals. The applicator and applicator system include a therapeutic surface which can receive a single dose of the pharmaceutical preparation and can be manipulated by the user to transfer and apply the pharmaceutical preparation on a body surface.Type: ApplicationFiled: May 10, 2019Publication date: June 17, 2021Applicant: Brickell Biotech, Inc.Inventors: Herbert Brinkman, John Koleng, Aron Aizenstat, Andrew Sklawer, Tatsuro Nagao, Masayoshi Takaoka
-
Publication number: 20210171460Abstract: A cocrystal containing the 1?R-diastereomer and the 1'S-diastereomer of sofpironium bromide at a ratio of 1:3 (Form CO), a crystal mixture (for example, Form B) containing Form CO and a crystalline form of the 1?R-diastereomer (Form MN), and a method for preparing sofpironium bromide, which is suitable for manufacture of the crystal mixture are provided. Form CO and a crystalline form of sofpironium bromide containing Form CO (for example, Form B) have superior stability without hygroscopic property, and accordingly they can be preferably used as a raw material of medicaments.Type: ApplicationFiled: November 25, 2020Publication date: June 10, 2021Applicants: Kaken Pharmaceutical Co., Ltd., Brickell Biotech, Inc.Inventors: Kazuyoshi MARUBAYASHI, Masahito WATANABE, Herbert R. BRINKMAN
-
Patent number: 9688624Abstract: Described herein is the DP2 antagonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.Type: GrantFiled: January 5, 2011Date of Patent: June 27, 2017Assignee: Brickell Biotech, Inc.Inventors: Jason Edward Brittain, Christopher David King, Brian Andrew Stearns
-
Patent number: 9572785Abstract: Described herein is the DP2 antagonist [2?-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4?-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.Type: GrantFiled: August 25, 2014Date of Patent: February 21, 2017Assignee: Brickell Biotech, Inc.Inventors: Jason Edward Brittain, Brian Andrew Stearns, Christopher David King, Kevin Ross Holme
-
Publication number: 20150259283Abstract: Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.Type: ApplicationFiled: May 22, 2014Publication date: September 17, 2015Applicant: BRICKELL BIOTECH, INC.Inventors: John J. Koleng, David Angulo